Addex Therapeutics Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was CHF 0.409417 million compared to CHF 0.682002 million a year ago. Net loss was CHF 4.11 million compared to CHF 3.6 million a year ago. Basic loss per share from continuing operations was CHF 0.09 compared to CHF 0.11 a year ago.
For the nine months, sales was CHF 0.830008 million compared to CHF 2.52 million a year ago. Net loss was CHF 17.15 million compared to CHF 10.93 million a year ago. Basic loss per share from continuing operations was CHF 0.42 compared to CHF 0.32 a year ago.